Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
Phase 4
Completed
- Conditions
- Schizophrenia
- Registration Number
- NCT00036088
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The purpose of this study is to determine how Olanzapine compares to an active comparator in the treatment of schizophrenia
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 530
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method